These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 32861140)
1. Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. Suda K; Murakami I; Obata K; Sakai K; Fujino T; Koga T; Ohara S; Hamada A; Soh J; Nishio K; Mitsudomi T Lung Cancer; 2020 Oct; 148():100-104. PubMed ID: 32861140 [TBL] [Abstract][Full Text] [Related]
2. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors. Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482 [TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. Suda K; Murakami I; Sakai K; Tomizawa K; Mizuuchi H; Sato K; Nishio K; Mitsudomi T Lung Cancer; 2016 Jan; 91():36-40. PubMed ID: 26711932 [TBL] [Abstract][Full Text] [Related]
4. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib. Oya Y; Yoshida T; Asada K; Oguri T; Inui N; Morikawa S; Ito K; Kimura T; Kunii E; Matsui T; Kubo A; Kato T; Abe T; Tsuda T; Hida T BMC Cancer; 2021 Jan; 21(1):57. PubMed ID: 33435905 [TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836 [TBL] [Abstract][Full Text] [Related]
6. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862 [TBL] [Abstract][Full Text] [Related]
7. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors. Wagener-Ryczek S; Heydt C; Süptitz J; Michels S; Falk M; Alidousty C; Fassunke J; Ihle MA; Tiemann M; Heukamp L; Wolf J; Büttner R; Merkelbach-Bruse S BMC Cancer; 2020 May; 20(1):408. PubMed ID: 32397977 [TBL] [Abstract][Full Text] [Related]
8. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. Suda K; Mizuuchi H; Murakami I; Uramoto H; Tanaka F; Sato K; Takemoto T; Iwasaki T; Sekido Y; Yatabe Y; Mitsudomi T Lung Cancer; 2014 Aug; 85(2):147-51. PubMed ID: 24939008 [TBL] [Abstract][Full Text] [Related]
9. Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). Zhong J; Li L; Wang Z; Bai H; Gai F; Duan J; Zhao J; Zhuo M; Wang Y; Wang S; Zang W; Wu M; An T; Rao G; Zhu G; Wang J J Thorac Oncol; 2017 Dec; 12(12):1766-1778. PubMed ID: 28818608 [TBL] [Abstract][Full Text] [Related]
10. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor ( Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206 [TBL] [Abstract][Full Text] [Related]
11. Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. Mizuuchi H; Suda K; Murakami I; Sakai K; Sato K; Kobayashi Y; Shimoji M; Chiba M; Sesumi Y; Tomizawa K; Takemoto T; Sekido Y; Nishio K; Mitsudomi T Cancer Sci; 2016 Apr; 107(4):461-8. PubMed ID: 26845230 [TBL] [Abstract][Full Text] [Related]
12. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study. Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921 [TBL] [Abstract][Full Text] [Related]
13. Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs. Dong Y; Zhou Z; Wang J; Ma L; Liu Z; Wang Y; Song J; Zhang S; Che N Pathol Res Pract; 2019 May; 215(5):946-951. PubMed ID: 30760406 [TBL] [Abstract][Full Text] [Related]
14. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916 [TBL] [Abstract][Full Text] [Related]
15. The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. Wang Y; Tian P; Xia L; Li L; Han R; Zhu M; Lizaso A; Qin T; Li M; Yu B; Mao X; Han-Zhang H; He Y Lung Cancer; 2020 Aug; 146():165-173. PubMed ID: 32540560 [TBL] [Abstract][Full Text] [Related]
16. First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience. Yu X; Zhang X; Zhang Z; Lin Y; Wen Y; Chen Y; Wang W; Zhang L Cancer Commun (Lond); 2018 Jul; 38(1):51. PubMed ID: 30055651 [TBL] [Abstract][Full Text] [Related]
17. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131 [TBL] [Abstract][Full Text] [Related]
18. Nanjo S; Arai S; Wang W; Takeuchi S; Yamada T; Hata A; Katakami N; Okada Y; Yano S Mol Cancer Ther; 2017 Mar; 16(3):506-515. PubMed ID: 28138027 [TBL] [Abstract][Full Text] [Related]
19. Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment. Iacono D; Osman GA; Migliorino MR; Grillo L; Remotti D; Nunnari J; Ricciardi S; Rossi A; Mancuso A; Graziano P; Di Lorenzo A; Bronzini M; Signora M; Leone A Am J Clin Oncol; 2019 Nov; 42(11):845-850. PubMed ID: 31644442 [TBL] [Abstract][Full Text] [Related]
20. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC. Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]